Quizartinib (Vanflyta)

From HemOnc.org - A Hematology Oncology Wiki

Revision as of 15:25, 8 June 2023 by Jwarner (talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

Note: this drug is only approved in Japan, at this time.

Mechanism of action

FLT3 inhibitor

Diseases for which it is used

FLT3+ AML

History of changes in PMDA indication

2019-06-18: Newly indicated for the treatment of relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia.

Also known as

Code names: AC220, ASP2689
Brand name: Vanflyta

Retrieved from "https://hemonc.org/w/index.php?title=Quizartinib_(Vanflyta)&oldid=72556"